Ibrutinib and idelalisib, B-cell receptor (BCR) signaling pathway inhibitors, have been
recently approved for use against relapsed/refractory chronic lymphocytic leukemia (CLL) …

Follicular lymphoma (FL) is the most common indolent B‐cell non‐Hodgkin lymphoma
(NHL) with genetic alterations of BCL‐2, KMT2B, and KMT6. FL is refractory to conventional …

The lack of BTK in X-linked agammaglobulinemia (XLA) patients does not affect monocytes
and polymorphonuclear cells (PMN) phenotype and functions. In this study, we show that …

Ibrutinib has B-cell signaling inhibitory activity that might be more potent than anti-CD20
monoclonal antibodies. HBVr in the case of chronic HBV carrier state or past HBV infection …

Ask a clinical immunologist for their first thought about Bruton tyrosine kinase (BTK) and the
answer most likely will be related to B cells and humoral immunodeficiency. Ask the same …

Ibrutinib is a selective oral Burton tyrosine kinase (BTK) inhibitor that interfering with the
downstream pathways of B-cell receptor signaling inhibits proliferation and induces …

Antibodies produced by B-cells provide protection from infectious agents. However,
impaired cell death signaling pathways in B-cells can lead to cancer, immunodeficiency or …

Monoclonal antibodies (MAbs) raised against cancer antigens may mediate antibody-
dependent cell-mediated cytotoxicity. This form of cancer control arises from cytolysis of a …